⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

NIHR CRUK Experimental Cancer Medicine Centre

h-index: 42
Total citations: 7,527
Total papers: 275

Homepage: https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/Facilities/Southampton-Experimental-Cancer-Medicine-Centre/NIHR-CRUK-Southampton-Experimental-Cancer-Medicine-Centre.aspx

Recent papers from NIHR CRUK Experimental Cancer Medicine Centre

A phase IIa study of the anti‐ PD ‐ L1 antibody avelumab in relapsed/refractory PTCL : The AVAIL ‐T trialBritish Journal of Haematology · 2026
Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone as First-Line Therapy for Patients With Diffuse Large B-Cell LymphomaJCO oncology advances. · 2026
UH-CAN Lung: Urine Home Collection for Lung Cancer Risk Assessment in Lung Cancer Screening Non-Responders – an observational, feasibility study protocolF1000Research · 2026
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.Journal of Clinical Oncology · 2026
Lamin B1 safeguards the B cell genome and shapes lymphoma outcomeHemaSphere · 2026
Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinomaMolecular Oncology · 2026
Histopathology-inferred spatial transcriptomics characterizes the tumor microenvironment in 1,500 head and neck tumors and predicts clinical outcomes2026
Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphomaHaematologica · 2026
Getting the guts right:Benchmarking faecal DNA extraction methods for comprehensive microbiota detection2026
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES StudyJournal of Clinical Oncology · 2025
FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastomaNature Communications · 2025
Genotoxic chemotherapy impedes complement dependent cytotoxicity via Chk1-mediated CD59 regulation2025
Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy responseMolecular Cancer · 2025
Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, EnrichBlood · 2024
One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort studyERJ Open Research · 2024
Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantationBone Marrow Transplantation · 2024
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.Journal of Clinical Oncology · 2024
Relationship between infiltration of tissue-resident memory T cells (TRM) in head and neck squamous cell carcinoma (HNSCC) tissue and localization and age.Journal of Clinical Oncology · 2024
Abstract PO1-18-06: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors – CONTRASTCancer Research · 2024
Assessment of body composition in breast cancer patients: concordance between transverse computed tomography analysis at the fourth thoracic and third lumbar vertebraeFrontiers in Nutrition · 2024